
GILD
GILEAD SCIENCES, INC.
Gilead Sciences는 바이러스성 질환, 암, 염증성 질환을 대상으로 의약품을 개발합니다.
공식 홈페이지 ↗다가오는 임상·규제 일정
앞으로 30일- 2026/12/12Anito-cel — fourth-line or later multiple myeloma회사 원문 ↗
Phase 2 data
- GEM-AnitoFIRST early results on December 12, 2026Anito-cel — GEM-AnitoFIRST회사 원문 ↗
Phase 2 data
- 2026/12/12Yescarta (axicabtagene ciloleucel)회사 원문 ↗
Data readout
일정 15건 더 보기
- 2026/12/12Yescarta (axicabtagene ciloleucel)회사 원문 ↗
Phase 2 data
- 2026/12/12Yescarta (axicabtagene ciloleucel)회사 원문 ↗
Data readout
- 2026/12/12Yescarta (axicabtagene ciloleucel)회사 원문 ↗
Data readout
- 2026/12/13Anito-cel — fourth-line or later multiple myeloma회사 원문 ↗
Data readout
- 2026/12/13Anito-cel — fourth-line or later multiple myeloma회사 원문 ↗
Data readout
- December 13, 2026 — bridging irradiation before axi-cel presentationYescarta (axicabtagene ciloleucel)회사 원문 ↗
Conference presentation
- 2026/12/13Yescarta (axicabtagene ciloleucel)회사 원문 ↗
Phase 1 data
- 2026/12/13om336회사 원문 ↗
Phase 1 data
- December 14, 2026 — GELTAMO LATE-R second interim analysisYescarta (axicabtagene ciloleucel)회사 원문 ↗
Phase 2 data
- 2026/12/14KITE-753회사 원문 ↗
Phase 1 data
- 2026/12/14Tecartus (brexucabtagene autoleucel)회사 원문 ↗
Conference presentation
- ASH 2026, December 12–15; session date unspecifiedYescarta (axicabtagene ciloleucel)회사 원문 ↗
Data readout
- Second CD19-directed CAR T-cell outcomes at ASH 2026, December 12–15Tecartus (brexucabtagene autoleucel)회사 원문 ↗
Data readout
- Rocca consortium CML analysis at ASH 2026, December 12–15Tecartus (brexucabtagene autoleucel)회사 원문 ↗
Data readout
- Extramedullary B-ALL analysis at ASH 2026, December 12–15Tecartus (brexucabtagene autoleucel)회사 원문 ↗
Data readout